{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:04:58Z","timestamp":1792242298110,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purposes<\/jats:title>\n                    <jats:p>Although next-generation sequencing (NGS) has allowed for the detection of mutations in acute myeloid leukemia (AML), the clinical relevance of variant allele frequency (VAF) for the majority of mutations is unknown. This study aimed to investigate whether the VAFs of AML-associated mutations could improve the prognostic classification in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bone marrow samples from 254 AML patients were included for targeted sequencing. Univariate Cox regression analyses identified mutations affecting survival, and optimal VAF cutoffs were determined by X-tile software. Multivariate Cox regression analyses were used to validate the independent prognostic value of the variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The presence of ASXL1, SF3B1, DNMT3A, and TP53 mutations had a significantly adverse effect on survival outcomes. High FLT3-ITD allelic ratio (\u226535%) and high mutation VAFs of ASXL1 (\u22652.8%), DNMT3A (\u226545%), DNMT3A R882 (\u226545%), NPM1 (\u226538%), NPM1 type A (\u226539%), SF3B1 (\u226510%), and TP53 (\u226510%) genes were the significant risk factors of overall survival (OS). Patients with high VAFs of bZIP in-frame mutated CEBPA (\u22652%) had favorable OS. Notably, the prognostic utility of VAF for ASXL1 and CEBPA was limited compared to their binary mutation status due to the relatively low cutoff values. Based on optimal VAF cutoff-based classifications of five genes (DNMT3A, FLT3-ITD, NPM1, SF3B1, and TP53), mutation status-based classifications of two genes (ASXL1 and CEBPA) and cytogenetic stratification according to European LeukemiaNet (ELN) 2022 guidelines, we developed a prognostic model. This model effectively stratified non-transplanted AML patients into low-, intermediate-, and high-risk groups in both the internal and external cohorts (all pairwise comparisons, P\u2009&amp;lt;.05). However, the model showed limited utility for prognostic stratification in transplant patients (P\u2009&amp;gt;.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed that beyond binary mutation status, the relative amount of mutations exerts a significant prognostic impact in AML patients, suggesting its potential integration into risk stratification systems to guide clinical management in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag099","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:30:05Z","timestamp":1773664205000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia"],"prefix":"10.1093","volume":"31","author":[{"given":"Li","family":"Zhao","sequence":"first","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1296-969X","authenticated-orcid":false,"given":"Jinming","family":"Wei","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riming","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8260-439X","authenticated-orcid":false,"given":"Yulan","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Laboratory Diagnosis, Yantai Yuhuangding Hospital Affiliated to Qingdao University , Yantai, Shandong 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026060408364281800_oyag099-B1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2026060408364281800_oyag099-B2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026060408364281800_oyag099-B3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3324\/haematol.2019.241117","article-title":"Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification","volume":"105","author":"Knorr","year":"2020","journal-title":"Haematologica"},{"key":"2026060408364281800_oyag099-B4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"2026060408364281800_oyag099-B5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"2026060408364281800_oyag099-B6","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"key":"2026060408364281800_oyag099-B7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026060408364281800_oyag099-B8","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2018-01-828467","article-title":"High npm1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML","volume":"131","author":"Patel","year":"2018","journal-title":"Blood"},{"key":"2026060408364281800_oyag099-B9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cncr.32566","article-title":"Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia","volume":"126","author":"Sasaki","year":"2020","journal-title":"Cancer"},{"key":"2026060408364281800_oyag099-B10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"2026060408364281800_oyag099-B11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"2026060408364281800_oyag099-B12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026060408364281800_oyag099-B13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint Recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"2026060408364281800_oyag099-B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00161-7","article-title":"Clinical implications of recurrent gene mutations in acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"2026060408364281800_oyag099-B15","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0158-5","article-title":"Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"2026060408364281800_oyag099-B16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/ajh.26314","article-title":"Development of TP53 mutations over the course of therapy for acute myeloid leukemia","volume":"96","author":"Alwash","year":"2021","journal-title":"Am J Hematol"},{"key":"2026060408364281800_oyag099-B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2026060408364281800_oyag099-B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020252","article-title":"Next generation sequencing in AML-on the way to becoming a new standard for treatment initiation and\/or modulation?","volume":"11","author":"Leisch","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026060408364281800_oyag099-B19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026060408364281800_oyag099-B20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.31885","article-title":"Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes","volume":"125","author":"Boddu","year":"2019","journal-title":"Cancer"},{"key":"2026060408364281800_oyag099-B21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060408364281800_oyag099-B22","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"key":"2026060408364281800_oyag099-B23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"key":"2026060408364281800_oyag099-B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026060408364281800_oyag099-B25","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"key":"2026060408364281800_oyag099-B26","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv"},{"key":"2026060408364281800_oyag099-B27","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"2026060408364281800_oyag099-B28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25544","article-title":"High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia","volume":"94","author":"Patel","year":"2019","journal-title":"Am J Hematol"},{"key":"2026060408364281800_oyag099-B29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.16239","article-title":"Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia","volume":"188","author":"Linch","year":"2020","journal-title":"Br J Haematol"},{"key":"2026060408364281800_oyag099-B30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3343\/alm.2016.36.5.399","article-title":"Correlation of NPM1 type A mutation burden with clinical status and outcomes in acute myeloid leukemia patients with mutated NPM1 type A","volume":"36","author":"Jo","year":"2016","journal-title":"Ann Lab Med"},{"key":"2026060408364281800_oyag099-B31","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/bloodadvances.2021004250","article-title":"Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML","volume":"5","author":"Narayanan","year":"2021","journal-title":"Blood Adv"},{"key":"2026060408364281800_oyag099-B32","doi-asserted-by":"publisher","first-page":"10340","DOI":"10.1002\/cam4.5764","article-title":"The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"key":"2026060408364281800_oyag099-B33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-019-1959-3","article-title":"Influence of DNMT3A r882 mutations on AML prognosis determined by the allele ratio in Chinese patients","volume":"17","author":"Yuan","year":"2019","journal-title":"J Transl Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag099\/68221687\/oyag099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag099\/68221687\/oyag099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag099\/68221687\/oyag099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:36:51Z","timestamp":1780576611000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag099\/8669812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag099","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"oyag099"}}